CARsgen Warning Letter Notes Company Paused Manufacture Following 483

Following an FDA inspection of its North Carolina facility that found inadequate personnel training, non-implementation of quality control procedures and scuttle fly larva on employee clothing, Shanghai-based CARsgen Therapeutics has been issued a Warning Letter.
Source: Drug Industry Daily